Revakinagene Taroretcel-lwey
Brand names: Encelto · Active ingredient: Revakinagene Taroretcel-Lwey
In short: ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).
What is Revakinagene Taroretcel-lwey used for?
ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel).
Revakinagene Taroretcel-lwey dosage
For intravitreal implantation only
• ENCELTO is administered by a single surgical intravitreal procedure performed by a qualified ophthalmologist.
• The recommended dose is one ENCELTO implant per affected eye. Each ENCELTO implant contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF) (NTC-201-6A cell line), a neurotrophic factor.
The ENCELTO implant insertion is a surgical procedure performed in an operating room under aseptic conditions by a qualified ophthalmologist.
Pre-Surgical Preparation
Inspect the ENCELTO packaging for any signs of damage or leakage.
Verify the use-by date.
Confirm that the disposable temperature recording device displays a checkmark at the top of the screen.
Ensure the liquid medium is at the correct pH using the provided pH color guide reference card.
Prepare the surgical field properly.
Surgical Steps
1. Preparing the Surgical Site
a. Create a 7x7 mm peritomy of the conjunctiva and Tenon’s capsule at the selected implantation site.
b. Place a corneal-limbal traction suture in the selected surgical quadrant (either inferotemporal or inferonasal) (Figure 1).
c. Maintain hemostasis of the underlying sclera and conjunctiva (Figure 1).
d. Using an MVR and 15-degree blade, create a 3.0 mm full-thickness sclerotomy 3.75 mm posterior and parallel to the limbus (Figure 2). Do not insert ENCELTO outside of the pars plana.
e. Confirm:
• The incision is full thickness.
• There is adequate hemostasis.
• There is no spanning uveal tissue.
2. Preparing the ENCELTO Implant
a. Open the inner container and expose the upper compartment and luer lock cap (Figure 3).
b. Unlock the luer lock cap by turning it counterclockwise once.
c. Lift the luer lock cap vertically to remove ENCELTO (attached to the gripper).
d. Rinse ENCELTO with at least 5 mL of sterile Balanced Saline Solution (BSS).
e. Keep ENCELTO moist by applying BSS every 10 minutes until insertion.
f. While holding the luer lock cap, pass a double-armed 9-0 polypropylene suture needle through ENCELTO’s fixation loop (Figure 4).
3. Implantation of ENCELTO
a. Gently open the sclerotomy incision and insert ENCELTO perpendicularly into the eye (Figure 5).
b. Ensure only the fixation loop is exposed.
c. Release ENCELTO from the gripper by squeezing the indicated region with forceps or a fine needle holder (Figure 6).
4. Securing the Implant
a. Secure ENCELTO by creating a 3-1-1 anchor knot with the polypropylene suture at the apex of the fixation loop (Figure 7).
b. Confirm ENCELTO is centered in the incision.
c. Pass each suture arm centrally through either side of the wound at 90-99% scleral depth (Figure 8).
d. …
How to take Revakinagene Taroretcel-lwey — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Discuss the following with the patient.
Advise patients that ENCELTO implantation may be associated with infectious endophthalmitis (eye infection), retinal tear and detachment (retina separates from the eye wall resulting in vision loss), vitreous hemorrhage (bleeding within the central cavity of the eye), implant extrusion, suture-related complications, cataract formation (clouding of the lens of the eye), severe vision loss, and delayed dark adaptation (ability of the eye to adjust from bright lighting conditions to dark lighting conditions) .
Instruct patients to seek immediate care from an ophthalmologist if they experience any signs or symptoms that could be associated with these events which may include the following:
An increase in floaters, the appearance of “spider webs”, flashing lights, sensitivity to light, or loss of vision or visual field;
Increasing eye pain, progressive redness in the white of the eye, a sudden sensation that something is in their eye (i.e., foreign body sensation) or eye discharge. …
Warnings & precautions
Do not take this medicine if: ENCELTO is contraindicated in patients with:
Active or suspected ocular or periocular infections.
Known hypersensitivity to Endothelial Serum Free Media (Endo-SFM)
Severe vision loss defined as three or more lines of visual acuity loss [≥15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] has occurred following ENCELTO implantation . Monitor patients for signs and symptoms of vision loss and manage as clinically indicated.
Infectious endophthalmitis may occur following ENCELTO implantation. Signs and symptoms of infectious endophthalmitis include progressively worsening eye pain, vision loss, or scleral and conjunctival injection. To mitigate the risk of endophthalmitis, use proper aseptic surgical technique for ENCELTO implantation . Monitor patients for signs or symptoms of infectious endophthalmitis. Remove ENCELTO implant if infectious endophthalmitis occurs and manage symptoms according to clinical practice.
Retinal tears and retinal detachment may occur following ENCELTO implantation. Signs and symptoms of retinal tears include acute onset of flashing lights, floaters, and/or loss of visual acuity. Signs and symptoms of retinal detachment may include progressive visual field loss and/or loss of visual acuity. Use standard vitreoretinal surgical techniques during ENCELTO implantation to minimize the risk of retinal tears and retinal detachment. Monitor for any signs or symptoms of retinal tear and/or retinal detachment. Treat rhegmatogenous retinal detachment and retinal tears promptly. Remove ENCELTO implant, if vitrectomy with a complete gas fill or silicone oil fill is required .
Vitreous hemorrhage, which may result in temporary vision loss, has occurred following ENCELTO implantation . …
Revakinagene Taroretcel-lwey side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety data described in this section reflects exposure to ENCELTO in two clinical trials, Study 1 (NTMT-03-A) and Study 2 (NTMT-03-B) and are pooled for analysis. A total of 117 patients received ENCELTO, and 111 patients underwent a sham procedure and were followed for a duration of 24 months .
Serious adverse reactions occurred in six patients (5%) including suture related complications (n=5) and implant extrusion (n=1).
Table 1 lists the most common adverse reactions that occurred in >2% patients and with higher frequency in ENCELTO group compared to Sham group in Study 1 and Study 2. …
About this medicine
ENCELTO (revakinagene taroretcel-lwey) implant, is single-dose, sterile, nonpyrogenic and retrievable.
ENCELTO is an allogeneic encapsulated cell-based gene therapy that contains 200,000 to 440,000 allogeneic retinal pigment epithelial cells expressing recombinant human ciliary neurotrophic factor (rhCNTF) (NTC-201-6A cell line) for surgical intravitreal placement.
ENCELTO consists of an opaque, semi-permeable white to off-white capsule surrounding a scaffold of polyethylene terephthalate (PET) yarn, loaded with rhCNTF secreting allogeneic retinal pigment epithelial cells (NTC-201-6A cell line). Each end of the semi-permeable capsule is sealed with medical grade methacrylate adhesive, and to one end a titanium fixation loop is attached. ENCELTO width is 1.2 ± 0.1 mm, length is 6.1 ± 0.4 mm, and its internal diameter is 0.88 ± 0.02 mm (Figure 17).
ENCELTO is packaged in a protective inner container within an orange to pink liquid hold medium referred to as Endothelial Serum Free Media (Endo-SFM), which is maintained sterile by a sealed outer container. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1ae9482a-b478-4e21-9166-b5fd52d3ef9c. Read the full official label on DailyMed.